Incretin-related therapies: Targeting
the underlying physiology and cardiometabolic factors
of type 2 diabetes

February 2009
This supplement was submitted by DIME and was supported by an educational grant from Amylin Pharmaceuticals, Inc. and Eli Lilly and Company.

The worldwide increase in obesity has led to a growing number of patients with type 2 diabetes, many of whom have insulin resistance.

This supplement will describe the physiology of incretin hormones in type 2 diabetes, discuss the risks and benefits of incretin-based therapies, and suggest a treatment plan to control hyperglycemia, obesity, and long-term complications.

Full text | PDF